Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Knockout drug screens

Nature Biotechnology volume 19, pages 919–920 (2001)Cite this article

Cell lines that differ by a single genetic change show promise in drug screens to identify compounds with gene-selective properties.

How does one discover drugs to treat diseases whose pathophysiology is poorly understood? This daunting question faces many researchers interested in alleviating disease, especially those working on cancer. Perhaps more than any other disease, cancer has frustrated efforts to understand and manage it, and there continues to be a great need for better therapeutics. In this issue, Torrance et al.1 introduce a new twist to top-down drug screening strategies, one that integrates fluorescence protein technology with somatic cell genetics, thereby capturing some of the appeal of molecular approaches.

This is a preview of subscription content, access via your institution

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

Buy

All prices are NET prices.

Figure 1: Co-culture drug screening with isogenic “knockout” cells.

© Bob Crimi

References

  1. Torrance, C.J. et al. Nat. Biotechnol. 19, 940–945 (2001).

    Article  CAS  Google Scholar 

  2. Huang, P.S. & Oliff A. Curr. Opin. Genet. Dev. 11, 104–110 (2001).

    Article  CAS  Google Scholar 

  3. Gibbs, J.B. Science 287, 1969–1973 (2000).

    Article  CAS  Google Scholar 

  4. Carpenter, C.L. & Cantley, L.C. Curr. Opin. Cell Biol. 8, 153–158 (1996).

    Article  CAS  Google Scholar 

  5. Campbell, V.W. et al. Am. J. Med. Sci. 307, 167–172 (1994).

    Article  CAS  Google Scholar 

  6. Koo, H.M., et al. Cancer Res. 59, 6057–6062 (2000).

    Google Scholar 

  7. Shirasawa, S. et al. Science 260, 85–88 (1993).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. senior director in the Cancer Research Group, The DuPont Pharmaceuticals Company, Glenolden Laboratory, 500 South Ridgeway Avenue, Glenolden, 19036, PA

    George C. Prendergast

Authors
  1. George C. Prendergast
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Prendergast, G. Knockout drug screens. Nat Biotechnol 19, 919–920 (2001). https://doi.org/10.1038/nbt1001-919

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt1001-919

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing